|This article needs additional citations for verification. (September 2014)|
|Classification and external resources|
Batten disease (also known as Spielmeyer-Vogt-Sjögren-Batten disease) is a rare, fatal autosomal recessive neurodegenerative disorder that begins in childhood. It is the most common form of a group of disorders called the neuronal ceroid lipofuscinoses (NCLs).
Although Batten disease is usually regarded as the juvenile form of NCL (or "type 3"), some physicians use the term Batten disease to describe all forms of NCL. Historically, the NCLs were classified by age of disease onset as infantile NCL (INCL), late infantile NCL (LINCL), juvenile NCL (JNCL) or adult NCL (ANCL).
Early symptoms of the disorder usually appear around ages 2–10, with gradual onset of vision problems, or seizures. Early signs may be subtle personality and behavior changes, slow learning or regression, repetitive speech or echolalia, clumsiness, or stumbling. There may be slowing head growth in the infantile form, poor circulation in lower extremities (legs and feet), decreased body fat and muscle mass, curvature of the spine, hyperventilation and/or breath-holding spells, teeth grinding, and constipation.
Over time, affected children suffer mental impairment, worsening seizures, and progressive loss of sight, speech and motor skills. Eventually, children with Batten disease become blind, bedridden, and demented, and die. Batten Disease is a terminal disease; life expectancy varies depending on the type or variation.
Batten disease is named after the British pediatrician Frederick Batten, who first described it in 1903. Also known as Spielmeyer-Vogt-Sjögren-Batten disease, it is the most common form of a group of disorders called neuronal ceroid lipofuscinosis (or NCLs). Although Batten disease is usually regarded as the juvenile form of NCL, some physicians use the term Batten disease to describe all forms of NCL.
Batten disease is inherited primarily in an autosomal recessive pattern, but it varies by age. In cases involving children, it is only inherited as an autosomal recessive trait. In adults, the inheritance pattern is still autosomally recessive but there is also a chance of it being inherited in an autosomal dominant fashion as well. Eight genes have been identified in the variety of NCLs, mutations in which contribute to the development of the phenotypic trait of the disorders:
- CLN1, also known as PPT1, encodes an enzyme called palmitoyl-protein thioesterase 1 that is insufficiently active in Infantile NCL.
- CLN 2, or TPP1, produces an enzyme called tripeptidyl peptidase 1—an acid protease that degrades proteins. The enzyme is insufficiently active in Late Infantile NCL (also referred to as CLN2).
- CLN3 mutation is the major cause of Juvenile NCL. The gene codes for a protein called CLN3 or battenin, which is found in the membranes of the cell (most predominantly in lysosomes and in related structures called endosomes). The protein’s function is currently unknown.
- CLN5, which causes variant Late Infantile NCL (vLINCL, also referred to as CLN5), produces a lysosomal protein called CLN5, whose function has not been identified.
- CLN6, which also causes Late Infantile NCL, encodes a protein called CLN6 or linclin. The protein is found in the membranes of the cell (most predominantly in a structure called the endoplasmic reticulum). Its function has not been identified.
- MFSD8, seen in variant Late Infantile NCL (also referred to as CLN7), encodes the MFSD8 protein that is a member of a protein family called the major facilitator superfamily. This superfamily is involved with transporting substances across the cell membranes. The precise function of MFSD8 has not been identified.
- CLN8 causes progressive epilepsy with mental retardation. The gene encodes a protein also called CLN8, which is found in the membranes of the cell—most predominantly in the endoplasmic reticulum. The protein’s function has not been identified.
- CTSD, involved with Congenital NCL (also referred to as CLN10), encodes cathepsin D, a lysosomal enzyme that breaks apart other proteins. A deficiency of cathepsin D causes the disorder.
The mutation causes the buildup of lipofuscins in the body's tissues. These substances consist of fats and proteins and form certain distinctive deposits that cause the symptoms and can be seen under an electron microscope. The diagnosis of Batten disease is based on the presence of these deposits in skin samples as well as other criteria. Eight genes have now been identified that cause different types of Batten disease in children or adults, more having yet to be identified. Two of these genes encode enzymes. The function of most of these genes is still unknown. The identification of these genes opens up the possibility of gene replacement therapy or other gene-related treatments. Batten disease is very rare and occurs in an estimated 2 to 4 out of every 100,000 births in the United States.
In many instances, Batten Disease is initially seen by an ophthalmologist during an eye exam because one of the first signs is vision loss. Even though it is also seen in a variety of other diseases as well, a loss of ocular cells should be a warning sign of Batten Disease potentially being present. If Batten Disease is a possible diagnosis for an individual, a variety of tests are run to confirm including:
Blood or urine tests. These tests can detect abnormalities that may indicate Batten disease. For example, elevated levels of a chemical called dolichol are found in the urine of many individuals with NCL. The presence of vacuolated lymphocytes—white blood cells that contain holes or cavities (observed by microscopic analysis of blood smears)—when combined with other findings that indicate NCL, is suggestive for the juvenile form caused by CLN3 mutations.
Skin or tissue sampling. The doctor can examine a small piece of tissue under an electron microscope. The powerful magnification of the microscope helps the doctor spot typical NCL deposits. These deposits are common in skin cells, especially those from sweat glands.
Electroencephalogram or EEG. An EEG uses special patches placed on the scalp to record electrical currents inside the brain. This helps doctors see telltale patterns in the brain's electrical activity that suggest an individual has seizures.
Electrical studies of the eyes. These tests, which include visual-evoked responses and electroretinograms, can detect various eye problems common in childhood NCLs.
Diagnostic Imaging using Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). Diagnostic imaging can help doctors look for changes in the brain's appearance. CT uses x-rays and a computer to create a sophisticated picture of the brain's tissues and structures, and may reveal brain areas that are decaying, or “atrophic,” in persons with NCL. MRI uses a combination of magnetic fields and radio waves, instead of radiation, to create a picture of the brain.
Measurement of Enzyme Activity. Measurement of the activity of palmitoyl-protein thioesterase involved in CLN1, the acid protease involved in CLN2, and, though more rare, cathepsin D activity involved in CLN10, in white blood cells or cultured skin fibroblasts (cells that strengthen skin and give it elasticity) can be used to confirm or rule out these diagnoses.
DNA Analysis. If families where the mutation in the gene for CLN3 is known, DNA analysis can be used to confirm the diagnosis or for the prenatal diagnosis of this form of Batten disease. When the mutation is known, DNA analysis can also be used to detect unaffected carriers of this condition for genetic counseling. If a family mutation has not previously been identified or if the common mutations are not present, recent molecular advanced have made it possible to sequence all of the known NCL genes, increasing the chances of finding the responsible mutation(s).
In June 1987, a Phase I clinical trial was launched at Weill Medical College of Cornell University to study a gene therapy method for treatment of the signs and symptoms of late infantile neuronal ceroid lipofuscinosis (LINCL). The experimental drug works by delivering a gene transfer vector called AAV2CUhCLN2 to the brain. Although the trial is not matched, randomized, or blinded and lacked a contemporaneous placebo/sham control group, assessment of the primary outcome variable suggests a slowing of progression of LINCL in the treated children.
In November 2006, after receiving FDA clearance, neurosurgeon Nathan Selden, pediatrician Bob Steiner, and colleagues at Doernbecher Children's Hospital at Oregon Health & Science University began a clinical study in which purified neural stem cells were injected into the brain of Daniel Kerner, a six-year-old child with Batten disease, who had lost the ability to walk and talk. This patient was the first of six to receive the injection of a stem cell product from StemCells Inc., a Palo Alto biotech company. These are believed to be the first-ever transplants of fetal stem cells into the human brain. By early December, the child had recovered well enough to return home, and it was reported that there were some signs of speech returning. Daniel Kerner died on April 12, 2010. The main goal of Phase I clinical trials, however, was to investigate the safety of transplantation. Overall, the Phase I data demonstrated that high doses of human neural stem cells, delivered by a direct transplantation procedure into multiple sites within the brain, followed by twelve months of immunosuppression, were well tolerated by all six patients enrolled in the trial. The patients’ medical, neurological and neuropsychological conditions, following transplantation, appeared consistent with the normal course of the disease.
In 2010, Cherie and Jim Flores donated $2 million, the biggest gift in Batten disease research history, and the Beyond Batten Disease Foundation contributed $500,000 to establish laboratories for Italian researchers Drs. Ballabio, Sardiello and their colleagues at the Jan and Dan Duncan Neurological Research Institute of Texas Children’s Hospital.
During 2011, the first controlled clinical trials began with the University of Rochester for a treatment for Batten Disease. The trial included 30 patients who were experiencing signs of the disease in the hope of slowing its progress.
In November 2013, Weill Medical College of Cornell University began recruiting participants for a safety study of a gene transfer vector, described as a non-randomised safety and efficacy trial. Additionally, in March 2014, the University of Rochester began recruiting for an 8-week trial on ambulatory children who are to be administered of mycophenolate mofetil.
|Wikimedia Commons has media related to Batten disease.|
- Hobert JA, Dawson G (October 2006). "Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future". Biochimica Et Biophysica Acta 1762 (10): 945–53. doi:10.1016/j.bbadis.2006.08.004. PMID 17049436.
- Rakheja D, Narayan SB, Bennett MJ (September 2007). "Juvenile neuronal ceroid-lipofuscinosis (Batten disease): a brief review and update". Current Molecular Medicine 7 (6): 603–8. doi:10.2174/156652407781695729. PMID 17896996.
- Cooper JD (June 2008). "Moving towards therapies for juvenile Batten disease?". Experimental Neurology 211 (2): 329–31. doi:10.1016/j.expneurol.2008.02.016. PMID 18400221.
- Cialone J, Adams H, Augustine EF; et al. (May 2012). "Females experience a more severe disease course in Batten disease". Journal of Inherited Metabolic Disease 35 (3): 549–55. doi:10.1007/s10545-011-9421-6. PMC 3320704. PMID 22167274.
- synd/7 at Who Named It?
- Batten FE (1902). "Cerebral degeneration with symmetrical changes in the maculae in two members of a family". Transactions of the Ophthalmological Societies of the United Kingdom 23: 386–90.
- http://www.bdsra.org/what-is-batten-disease/about-batten-disease/[full citation needed]
- NIH[verification needed]
- Clinical trial number NCT00151216 for "Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis" at ClinicalTrials.gov
- Worgall S, Sondhi D, Hackett NR; et al. (May 2008). "Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA". Human Gene Therapy 19 (5): 463–74. doi:10.1089/hum.2008.022. PMID 18473686.
- "A stem cell first at OHSU" The Portland Tribune, Nov 24, 2006
- http://www.technologyreview.com/read_article.aspx?id=17888&ch=biotech[full citation needed]
- "StemCells: Enter Date".
- http://www.medicalnewstoday.com/releases/227090.php[full citation needed]
- Clinical trial number NCT01161576 for "Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis" at ClinicalTrials.gov
- Clinical trial number NCT01399047 for "Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JUMP)" at ClinicalTrials.gov
- http://bdfa-uk.org.uk UK Batten Disease Family Association
- Batten disease at University of Rochester Medical Centre
- Batten Disease at NINDS
- GeneReviews/NCBI/NIH/UW entry on Neuronal Ceroid-Lipofuscinosis
- About Batten Disease
- NCL resource - Batten disease at University College London
- Batten Disease Support and Research Association (bdsra.org)
- What is Batten? at lrbf.org
- Batten Disease Support and Research Organisation (Australia)
- Batten FE, Mayou MS (1915). "Family Cerebral Degeneration with Macular Changes". Proceedings of the Royal Society of Medicine 8 (Sect Ophthalmol): 70–90. PMC 2003604. PMID 19978990.
- Living with Batten Disease on YouTube